Wall Street analysts do a great job researching and following big, widely held, and actively traded companies such as EMC (NYSE: EMC ) , Comcast (Nasdaq: CMCSA ) , and Hewlett-Packard (NYSE: HPQ ) . That's their job, after all, and 20 or more sell-side analysts follow each one of these names.
You can't blame them for this big-company bias. Those are the stocks that give their firms the most business in both the banking and trading departments.
And while big companies are an integral part of any portfolio, they aren't the stocks individual investors like you and I can buy to generate the highest possible returns over the long run.
From the horse's mouth
In his recent book, Full of Bull, former Wall Street tech analyst Stephen T. McClellan says individual investors can take advantage of the fact that "analysts miss titanic secular shifts." He explains:
Analysts rarely take seriously the emerging companies that are pioneering a new wave. ... They fail to give proper credence to up and coming companies that represent a disruptive market leapfrog. ... Because the status quo is easier, they often miss the boat when a new force emerges.
McClellan recounts how he discounted Microsoft in the 1980s, because he thought it was no different than other start-up software companies of the time, such as Lotus and Borland. "I paid the price for my oversight," he says bluntly.
Another case of expensive oversight
A more recent example of analyst oversight is the medical-device industry circa 2005. While entrenched stalwarts such as Johnson & Johnson (NYSE: JNJ ) and Stryker (NYSE: SYK ) got the coverage, a small robotic surgical equipment company, Intuitive Surgical (Nasdaq: ISRG ) , was showing signs of promise. Its revenue grew 51% in 2004; it held a near-monopoly in its market niche; and its breakthrough minimally-invasive surgical technology was gaining favor among doctors and patients.
Granted, you would have subjected your savings to greater volatility with Intuitive Surgical, and there wasn't (and still isn't) a lot of analyst coverage on it, so you would have had to do a lot of your own research. Taking the "safe" route by investing in larger medical-device companies might have seemed more attractive on a risk-reward basis.
The foresight and extra research, however, would have paid off. Over the past four years, Johnson & Johnson and Stryker are flat, while Intuitive Surgical has returned 150%, even after recent market volatility.
Leave your comfort zone
Looking for the next ultimate growth stock among those the Street has already discovered is futile. By the time analysts catch on to a revolutionary company, the jig is usually up.
The problem for individual investors is finding these industry-changing (sometimes world-changing) companies before Wall Street does. Fool co-founder David Gardner and his Motley Fool Rule Breakers team have made it their mission to find these stocks early on, then ride them to tremendous returns.
In fact, they first recommended Intuitive Surgical to subscribers in March 2005. They said, "The company is only lightly followed by Wall Street -- just four analysts cover it -- so we have the advantage of getting in before the crowds. We expect the company's future performance to be about as subtle as a brick through a window."
A brick through a window indeed -- that pick has since returned 130% for Rule Breakers subscribers.
If you need help finding tomorrow's big winners, you can get a full-access, 30-day trial of Rule Breakers, free of charge. There's no obligation to subscribe. Just click here to get started.
This article was first published Feb. 25, 2008. It has been updated.
Todd Wenning does not endorse throwing bricks through windows, except in the metaphorical sense. He does not own shares of any company mentioned. Johnson & Johnson is a Motley Fool Income Investor pick. Microsoft is an Inside Value recommendation. Intuitive Surgical is a Rule Breakers selection. The Fool owns shares of Stryker. The Fool's disclosure policy is groundbreaking.